236 related articles for article (PubMed ID: 32220884)
1. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
2. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
3. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
4. "The emerging role of capivasertib in breast cancer".
Andrikopoulou A; Chatzinikolaou S; Panourgias E; Kaparelou M; Liontos M; Dimopoulos MA; Zagouri F
Breast; 2022 Jun; 63():157-167. PubMed ID: 35398754
[TBL] [Abstract][Full Text] [Related]
5. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
6. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M
Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570
[TBL] [Abstract][Full Text] [Related]
7. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
8. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
10. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
11. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
12. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
15. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639
[TBL] [Abstract][Full Text] [Related]
18. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Schwartzberg LS; Vidal GA
Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
